Brinda Balakrishnan, M.D., Ph.D., joined BioMarin in early 2016 and currently serves as our Chief Business Development Officer. Dr. Balakrishnan leads our company’s initiatives on corporate strategy, mergers and acquisitions and licensing.
Prior to joining BioMarin, Dr. Balakrishnan was the Co-founder and Vice President of Corporate Strategy and Product Development at Vision Medicines, Inc., a start-up focused on developing treatments for rare ophthalmic diseases. In that role, she was responsible for in-licensing assets from big pharma and academia, fundraising and advancing a program for the treatment of Stargardt Disease. Before Vision Medicines, she spent two years as a consultant at McKinsey & Company in the healthcare practice, serving clients across small biotech, large pharma and provider groups on topics related to corporate strategy, corporate and business development and operations. Prior to McKinsey, Dr. Balakrishnan was in business development at Genzyme.
Dr. Balakrishnan earned a B.S. from the Massachusetts Institute of Technology (MIT) in chemical engineering and a Ph.D. from MIT in biomedical engineering and chemical engineering. She also earned an M.D. from Harvard Medical School and conducted her medical training in internal medicine at Beth Israel Deaconess Medical Center in Boston, a Harvard hospital. In addition, Dr. Balakrishnan serves as executive Leader Liaison to the BioMarin Working Parents Community Resource Group.